DRUG | Ticker Profile - Titan Protect

DRUG

Bright Minds Biosciences Inc.

Healthcare · Biotechnology · NCM

$69.00

Data: 2026-05-28

✗ ETHICAL FAIL

Unknown MOAT

MODERATE

Data Confidence: 71.4%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$854M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-9.95

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-15.0%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$144.12

+109% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 3 analysts covering this stock

About Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.

https://brightmindsbio.com

Country: United States Employees: 26 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% N/A

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.857

Good returns relative to risk taken

Kelly Fraction

0.2995

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

13.620

Returns exceed worst-case losses — strong risk profile

Annual Return

793.7%

Historical annualised return based on price data

Max Drawdown

-58.3%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

384

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

-0.19

Very low correlation to market moves

52W High

$123.75

44% below the year high

52W Low

$23.18

198% above the year low

Avg Volume

185,240

Average daily shares traded — higher means easier to buy and sell

Short Ratio

4.1

Days it would take all short sellers to cover — higher means more crowded

Short % Float

10.0%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-2.50

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.03

Conservative use of debt — low financial risk

Current Ratio

81.48

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

81.10

Like current ratio but excludes inventory — stricter test

Gross Margin

0.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

0.0%

Profit from core operations before interest and tax

Free Cash Flow

$-13,104,564

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-27,353,518

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$218.67

Target Median

$144.12

Target Low

$143.25

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go